December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Barinthus Biotherapeutics plc - American Depositary Shares (NQ:BRNS)

0.5577 -0.0123 (-2.16%)
Streaming Delayed Price Updated: 1:20 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Barinthus Biotherapeutics plc - American Depositary Shares

< Previous 1 2 Next >
News headline image
Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether TBRG, SILA, BRNS are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages HFWA, BRNS, FITB Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages HFWA, FITB, AVDL, BRNS Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates DAY, BRNS, ETNB, VRNT on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECO, BRNS, VRNT on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
BRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Barinthus Biotherapeutics plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Q2 Virtual Investor Summit: Presentations Available Now
Via ACCESS Newswire
News headline image
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
Via ACCESS Newswire
News headline image
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
News headline image
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
Via ACCESS Newswire
News headline image
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
From Barinthus Biotherapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.